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QALY, and $100,000/QALY. The proportions of sensi-
tivity analyses reporting quantitative results that crossed
the threshold above the base case CU ratio were 23% for
cost sensitivity analyses, 38% for quality-of-life sensitiv-
ity analyses, and 15% for discount rate sensitivity analy-
ses. There was no difference in quality ratings between
CUAs that reported sensitivity analysis results that
exceeded the thresholds (N = 17) and those that did not,
but the overall quality and completeness ratings were only
moderate. CONCLUSIONS: Sensitivity analyses for eco-
nomic parameters are widely reported and can be used to
identify whether choosing different assumptions leads to
a different decision. Different decisions occur more fre-
quently for cost and quality-of-life assumptions than for
discount rate assumptions. Sensitivity analyses for cost
and quality-of-life parameters should be used to test alter-
native guideline recommendations, but sensitivity analy-
ses for discount rates do not have the same import.
Adhering to recommendations on performing cost-
effectiveness analyses would improve the overall quality
of these types of studies.
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Although a pharmacoeconomic model is usually created
for one setting, there is often interest in using it in other
jurisdictions. This requires that it be modiﬁable by other
users, and given the complexity of most models, this 
may be difﬁcult to do. OBJECTIVE: To develop a low
cost tool that standardizes model inputs and outputs 
and allows models to be easily edited and analyzed.
METHODS: An electronic viewer (MODEL-IT®) was
developed as a “container” that allows display and inter-
action with disease models. The tool is programmed to
work as a stand-alone application in a Windows© envi-
ronment. It is designed to read any model that has been
formatted according to a simple set of rules. The model
engine itself can be in any format, including EXCEL. The
screens were developed to maintain a consistent format
yet be able to display inputs and outcomes pertinent to
the speciﬁc model. Tool functions are accessed by self-
explanatory buttons. RESULTS: MODEL-IT® classiﬁes
inputs into speciﬁc categories including population 
characteristics, disease parameters, model controls (e.g.
number of replications), treatment details and costs. All
ﬁelds are editable. Outcomes are model-speciﬁc but are
also classiﬁed into costs, effectiveness, survival and cost-
effectiveness. Model versions can be saved for later use,
and all screens can be printed or exported to other pro-
grams. Model documentation can be incorporated as 
a help ﬁle. The Model-IT® viewer is available free of
charge. CONCLUSIONS: A viewer has been developed
to allow users to interact with models in a standard
format and to increase interdisciplinary access and under-
standing of models in order to support their wider use in
decision-making about new pharmaceuticals.
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OBJECTIVES: Our objectives were to investigate: 1)
whether methods and reporting of published cost-utility
analyses (CUAs) have improved over time; and 2)
whether quality is higher in journals that published more
CUAs. METHODS: A systematic search of the English-
language medical literature identiﬁed 522 original CUAs
published from 1976 through 2001. Each study was inde-
pendently audited by two trained readers for a core set
of data elements on study methodology and reporting,
and a subjective assessment of overall study quality on 
a scale from 1 (low) to 7 (high)—data available at:
http://www.hsph.harvard.edu/cearegistry/. High-volume
journals were deﬁned as those publishing 4 or more CUAs
from 1976–2001. This study updates our previous analy-
sis, which examined the quality of CUAs from 1976 to
1997. RESULTS: Several key elements improved over
time. Comparing the 1998–2001 period (n = 294) to
1976–1997 (n = 228), articles improved in: clearly pre-
senting the study perspective (73% vs. 52%, p < 0.001);
performing sensitivity analyses (93% vs. 89%, p = 0.092);
discounting both costs and QALYs (82% vs. 72%, p =
0.016); and calculating and reporting incremental ratios
(69% vs. 46%, p < 0.001). More studies in the latter
period took the societal perspective (30% vs. 23%). The
overall quality score improved as well, though the change
was not signiﬁcant (4.25 vs. 4.10, p = 0.19). The pro-
portion of studies disclosing funding sources did not
change (64% vs. 65%, p = 0.88). Average quality score
is greater in higher- vs. lower-volume journals (4.5 vs. 3.7,
p < 0.001). CONCLUSION: Published CUAs have
improved over time, though many still omit basic ele-
ments. Clinical journals, particularly those with little
experience publishing CUAs, need to adopt and enforce
standard protocols for conducting and reporting.
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OBJECTIVES: Economic evaluation is increasing
common in clinical trials. Often, individuals’ health care
costs are not observed in these trials, rather health care
cost estimates are often calculated from observed resource
